ClinicalTrials.gg
CompletedNCT01556451Updated Apr 12, 2017Results posted

ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

A Phase 4 interventional study of Zoster Vaccine Live in Herpes Zoster and Shingles, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
13th of 29
180 · median 160
Started
2012
with 3 others
Phase 4
8 of 29
none open now
Registered
18th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 13th largest by enrollment, is one of 4 that started in 2012, is one of 8 in phase 4, and was the 18th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study. Each subject will receive a single dose of ZOSTAVAX™. No statistical hypothesis testing will be conducted in the study.

03

Conditions studied

  • Herpes Zoster
  • Shingles

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No fever on day of vaccination
  • Females have a negative pregnancy test and use an acceptable method of , or are
  • Underlying chronic illness must be stable

Exclusion criteria

Exclusion Criteria:

  • History of reaction to any vaccine component
  • Prior history of herpes zoster
  • Prior receipt of varicella or zoster vaccine
  • Pregnant or breastfeeding
  • Have recently received immunoglobulins or blood products other than autologous blood transfusion
  • Received any inactivated other within 4 weeks prior to vaccination, or is expected to received any other live virus vaccine during the duration of the study
  • Received any inactivated vaccine within 7 days prior to vaccination, or is expected to receive any inactivated vaccine during the duration of the study
  • Use of therapy
  • Known or suspected immune dysfunction
  • Use of nontopical antiviral therapy with activity against herpes virus
  • Known or suspected active untreated tuberculosis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Zoster Vaccine Live

    Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1

    Biological: Zoster Vaccine Live

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody

    Blood samples collected prevaccination on Day 1 and Week 4 postvaccination were analyzed using a glycoprotein enzyme-linked immunosorbent assay (gpELISA) to detect Immunoglobulin G antibody to VZV. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 4 postvaccination / Day 1 (Baseline).

    Time frame: Day 1 (Baseline) and Week 4 postvaccination

  2. Geometric Mean Titer (GMT) of VZV Antibody

    Blood samples collected prevaccination on Day 1 and Week 4 postvaccination were analyzed using a gpELISA to detect Immunoglobulin G antibody to VZV

    Time frame: Day 1 (Baseline) and 4 weeks postvaccination

  3. Percentage of Participants With Clinical Adverse Experiences

    An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.

    Time frame: Up to 42 days postvaccination

  4. Percentage of Participants Discontinued Due to Clinical Adverse Experiences

    Time frame: Up to 42 days postvaccination

07

Results

Posted Sep 23, 2013

Participant flow

Participant flow — Overall Study
MilestoneZoster Vaccine Live
Started180
Completed180
Not completed0

Outcome measures

PrimaryGeometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody

Blood samples collected prevaccination on Day 1 and Week 4 postvaccination were analyzed using a glycoprotein enzyme-linked immunosorbent assay (gpELISA) to detect Immunoglobulin G antibody to VZV. The GMFR reports the geometric mean of the ratio of individual participant VZV antibody titers at Week 4 postvaccination / Day 1 (Baseline).

Time frame:
Day 1 (Baseline) and Week 4 postvaccination
Reported as:
Geometric mean · Ratio
Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody
RatioZoster Vaccine Live
Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody2.8 (2.5 to 3.1)
PrimaryGeometric Mean Titer (GMT) of VZV Antibody

Blood samples collected prevaccination on Day 1 and Week 4 postvaccination were analyzed using a gpELISA to detect Immunoglobulin G antibody to VZV

Time frame:
Day 1 (Baseline) and 4 weeks postvaccination
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titer (GMT) of VZV Antibody
gpELISA units/mLZoster Vaccine Live
Day 1 (Baseline)66.9 (59.2 to 75.5)
Week 4 postvaccination185.4 (167.0 to 205.9)
PrimaryPercentage of Participants With Clinical Adverse Experiences

An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an adverse experience.

Time frame:
Up to 42 days postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Adverse Experiences
Percentage of ParticipantsZoster Vaccine Live
Injection site adverse experiences53.3
Non-injection site adverse experiences24.4
PrimaryPercentage of Participants Discontinued Due to Clinical Adverse Experiences
Time frame:
Up to 42 days postvaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinued Due to Clinical Adverse Experiences
Percentage of ParticipantsZoster Vaccine Live
Percentage of Participants Discontinued Due to Clinical Adverse Experiences0

Adverse events

Collected over Up to 42 days postvaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zoster Vaccine Live—3/180 (1.7%)96/180 (53.3%)
Most frequent serious events
Most frequent serious events
EventZoster Vaccine Live
Anal FistulaGastrointestinal disorders1/180
Gastric PolypsGastrointestinal disorders1/180
Spinal Compression FractureInjury, poisoning and procedural complications1/180
Most frequent other events
Most frequent other events
EventZoster Vaccine Live
Injection-Site ErythemaGeneral disorders81/180
Injection-Site SwellingGeneral disorders68/180
Injection-Site PainGeneral disorders50/180

Baseline characteristics

Age, Customized
Age, Customized(Participants)Zoster Vaccine Live
Between 50 and 59 years89
60 years or older91
Sex: Female, Male
Sex: Female, Male(Participants)Zoster Vaccine Live
Female136
Male44
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Choi WS, Choi JH, Choi JY, Eom JS, Kim SI, Pai H, Peck KR, Sohn JW, Cheong HJ. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX) in Korean Adults. J Korean Med Sci. 2016 Jan;31(1):13-7. doi: 10.3346/jkms.2016.31.1.13. Epub 2015 Dec 24. PubMed 26770032 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2012
First posted
Mar 16, 2012
Start
Apr 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results first posted
Sep 23, 2013
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01556451
Responsible party
Sponsor
First posted
Mar 16, 2012
Start date
Apr 2012
Primary completion
Oct 2012
Completion
Oct 2012
Results posted
Sep 23, 2013
Last update
Apr 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion